Please ensure Javascript is enabled for purposes of website accessibility

Robots Power Profits at Intuitive Surgical

By Todd Campbell - Oct 21, 2017 at 12:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's third-quarter earnings came with some disclaimers, but the long-term performance of this company is impressive.

Intuitive Surgical (ISRG 2.69%) recently provided investors with its third-quarter financial report card, and the company delivered high marks for system placements and sales and procedure growth. Net income increased, too. But there are a few caveats investors should know about. Is this robotic surgery stock still a buy?

Digging into the details

Surgeons are already commonly using Intuitive Surgical's da Vinci system to assist them during urological procedures, and increasingly, they're using the system to help them perform general surgery, including colorectal and hernia procedures.

A man points at a bar chart in front of him showing increasingly taller columns.

IMAGE SOURCE: GETTY IMAGES.

As a result, hospitals are buying more da Vinci systems and procedure volume is growing. In the third quarter, the number of systems shipped to surgery centers increased 26%, to 169, and procedure volume grew 15% year over year.

System sales, instrument and accessory sales, and service revenue all improved in the quarter. Total revenue was $806 million, up 18% from last year. System sales contributed $258 million, and instrument and accessory revenue grew in line with procedure volume, to $401 million. Service revenue was the laggard, but it still improved 13%, to $147 million.

As for the bottom line, net income clocked in at $297.5 million, up from $211 million in Q3 2016, and adjusted earnings per share increased to $2.77 from $2.06 last year.

There are some disclaimers associated with these numbers, however -- namely, the net income increase wasn't because Intuitive Surgical spent less per dollar of sales on selling, general, and administrative expenses (SG&A). In fact, the company spent more for every dollar of revenue on that line item in the third quarter than last year. Research and development expenses also increased as a percentage of revenue from last year, but that's less worrisome because innovation is critical to expanding da Vinci's use.

In the following table, I'm including some line items from the company's Q3 income statement that are important to understanding Intuitive Surgical's numbers last quarter.

 Metric Q3 2017 Percentage
of Sales
Q3 2016 Percentage of Sales
Revenue (millions) $806.1   $682.9  
Operating expenses:        
Selling, general, and administrative $204.8 25.41% $168.0 24.60%
Research and development $83.4 10.35% $62.6 9.17%
Total operating expenses $288.2 35.75% $230.6 33.77%
Income from operations $278.6 34.56% $256.4 37.55%
Net income $297.5 36.91% $211.0 30.90%

Data source: Intuitive Surgical's third-quarter income statement. Chart by author.

As you can see in the above table, operating income as a percentage of sales decreased from last year, so net increasing net income wasn't due to operating efficiencies. Instead, it was because of tax items. GAAP and non-GAAP earnings per share were boosted by a one-time tax benefit of $0.59 in the quarter. As a result, the company went from spending $55.8 million on income tax last year to enjoying an $8.1 million benefit for income taxes in Q3, 2017.

Metric Q3 2017 Q3 2016
Income tax (benefit) expense -$8.1 $55.8

Data source: Intuitive Surgical's third-quarter income statement. Chart by author.

What's the takeaway?

Investors should be particularly happy with Intuitive Surgical's rising system placements because these additional systems should translate into more procedures and higher recurring revenue in the future. The 15% procedure growth is also bullish.

The rate remains nicely above the 9% to 12% growth-range forecast at the start of the year, despite decelerating slightly quarter over quarter, and it led management to increase its range for procedure growth to between 15% to 16% this year from between 14% to 15% exiting Q2.

The uptick in SG&A as a percentage of sales isn't great news because ideally, sales growth is leveraged against fixed costs for margin expansion. Instead, margin declined last quarter year over year. However, there's bound to be lumpiness in these metrics as the company grows, so it can be helpful to step back and consider a longer-term comparison.

For example, Intuitive Surgical's Q3 2017 revenue was 36.6% higher than Q3 2015, and its 34.6% operating margin handily outpaced the 32.2% rate from two years ago. The following chart adds a bit of additional perspective on how growing use of its surgical robots has translated into growth over time. While net income faces headwinds from higher operating expenses this year, I think this chart shows why you might not want to worry too much about it.

ISRG Revenue (TTM) Chart

ISRG Revenue (TTM) data by YCharts.

Overall, I believe there's a massive opportunity for Intuitive Surgical's sales to expand as it moves into additional procedure indications. This remains one of my favorite stocks to own in long-term growth portfolios.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$206.10 (2.69%) $5.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.